ClinicalTrials.Veeva

Menu

Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer

Lahey Health logo

Lahey Health

Status

Completed

Conditions

Endometrial Cancer
Sentinel Lymph Node Detection

Treatments

Procedure: ICG Dye

Study type

Interventional

Funder types

Other

Identifiers

NCT02131558
2014-017

Details and patient eligibility

About

Patients with endometrial cancer who have planned robotic laparoscopic hysterectomy and full bilateral pelvic and para-aortic lymphadenectomy will receive injections of a fluorescent dye, Indocyanine green (ICG). ICG spreads through the lymphatic system, and will be visualized using near-infrared (NIR) imagers. Upon visualization of the path of the ICG, sentinel lymph nodes (SLNs), the first nodes to receive drainage from the primary tumor, will be identified. SLNs will be surgically removed and provided to Pathology for evaluation. Non-sentinel nodes will also be surgically removed, as is consistent with routine medical care for these patients, and given to Pathology for evaluation. A positive SLN may be the most accurate identifier of the extra-uterine spread of disease, and will provide information about the extent of surgical node removal necessary.

Enrollment

7 patients

Sex

Female

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult women patients (>18 years of age and <90 years of age)
  • Research authorization (consent)
  • Pre-operative diagnosis of clinical Stage 1 endometrial cancer
  • Pre-operative indications of grade 3 tumor, and/or tumor size greater than 2 cm in size
  • Scheduled and consented to undergo robotic hysterectomy and surgical staging, including bilateral pelvic and para-aortic lymphadenectomy

Exclusion criteria

  • Severe coagulopathy or severe thrombocytopenia
  • Severe anemia
  • Severe cardio-pulmonary comorbidities demanding minimization of operative time
  • History of liver disease
  • Iodide allergy
  • Emergent operation
  • Additional surgical risk as determined during surgery at the discretion of the attending
  • Impaired capacity to make informed medical decisions

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

7 participants in 1 patient group

ICG Dye
Experimental group
Description:
Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
Treatment:
Procedure: ICG Dye

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems